Benefit-Risk Frameworks May Be Coming To US FDA Advisory Committees
Structured assessments, which are currently publicly available only for approved products, could help frame questions for panel discussion of specific drugs under review; FDA also exploring ways to make completed frameworks more readily accessible.
You may also be interested in...
Legislative proposal in FY 2020 budget request wouldn't necessarily reduce number of complete response letters, but ability to require reports and postmarket changes on quality issues might eventually create more flexibility during initial product reviews.
US FDA seeks White House approval for to contract for interviews with 100 to 150 active commercial IND holders.
Dedicated mechanism may be needed for biopharma sponsors and patient advocacy groups to talk to agency about patient experience data collection and analysis; industry wants FDA to clarify where such data will appear in product labeling, while advocates ask agency to be mindful of limited resources many patient groups have for conducting such research.